Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer.
Five phase III randomized trials used to develop prognostic and predictive AI biomarkers.
Over 16,000 digitized slides from > 5000 patients
Both AI biomarkers featured as selected oral presentations at 2022 ASCO GU, and presented by Dr. Osama Mohamad and Dr. Daniel Spratt
Osama Mohamad, MD
Daniel Spratt, MD
Case Western Reserve University